Background We aimed to evaluate the long-term clinical outcomes of Toric intraocular lens (Toric IOL)and Acrysof IQ Restor Toric +3.0D intraocular lens (ART +3.0D IOL)in patients with cataract and corneal astigmatism.Methods Fifty-eight eyes (46 participants) that had Toric IOL implantation, forty-three eyes (31 participants) that had ART +3.0D IOL implantation, were included in the study. All participants were assessed preoperatively, 3, 6, 12 and 24 months postoperatively. Primary outcomes measure: uncorrected distance visual activity (UCDVA), uncorrected near visual acuity (UCNVA), astigmatism and IOL axis alignment, defocus curve, contrast sensitivity and ocular aberration.Results UCDVA was better than 0.3 LogMAR at 3, 6, 12 and 24 months after surgery in both groups, and UCDVA was significantly improved after surgery than before ( P <0.05). All patients with ART +3.0D IOL implanted after surgery achieved or exceeded the near-vision of Jr3, which could meet the needs for removal of lens. At 3, 6, 12 and 24 months after surgery, the residual astigmatic was (0.28±0.20) diopters(D), (0.32±0.25) D, (0.31±0.16) D, (0.32±0.22) D in Toric group, and (0.27±0.17) D, (0.31±0.21) D, (0.30±0.19) D, (0.33±0.20) D respectively in the ATR group. Compared with preoperative corneal astigmatism, the difference was statistically significant ( P <0.05). The IOL axial mobility of all the patients was less than 5°in the two groups within 2 years after the operation. There was no difference in aberrations between the ART group and the Toric group under 3mm pupil, and there was statistically significant difference between the ART group and the Toric group under 5mm pupil ( P <0.05).Conclusions Toric IOL and ART + 3.0D IOL implantation were safe and effective in the treatment of cataract with corneal astigmatism,and ART + 3.0D IOL provided adequate near vision. The effect had long-term stability.